Abstract 391P
Background
Lip cancer represents 1-2% of malgnancies and accounts for 23.6-30% of all oral cancers. It is more common in the lower lip, However, it may appear in the upper lip also. Squamous cell carcinoma is the most common subtype. There is limited data to evaluate racial disparites into different age groups. So this study aims to evaluate the long-term survival outcome for lip cancer in the young and adults compared to the elderly and consider racial disparities.
Methods
Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) Program. We obtained data of patients diagnosed with lip cancer from 2000-2020. The age groups have been classified into two groups according to the National Institute of Age and divided into young and adults if less than 65 years while the old age starting from 65 years.
Results
The majority were Caucasians (99279 patients) and 114 only were African Americans. The 5-year relative survival for lip cancer in the young and adults age group was 92.6%, while in the old age group was 88.9%; P>0.0001. The 5-year relative survival of African Americans in the young and adult age was 85.9% while for Caucasiasns it was 92.5%, and in African Americans elderly the 5-year relative survival was 60.4% while in Caucasian was 88.9%; P >0.0001. The 5-year relative survival for lip cancer in localized SEER stage at the young and adults age group was 95.4%, while in the old age group 92.4% And the 5-year relative survival for lip cancer in distant stage of the disease at young and adults age group was 52.1%, while in the old age group it was 27.7%. Patients treated with combined chemoradiotherapy had a 5-year relative survival of 52.3%, while those who had no systemic therapy had a 5-year relative survival of 93.2%.
Conclusions
In this study, the results highlight significant differences in the long-term survival outcomes; Caucasians are more susceptible to devolop lip cancer than African Americans. However, African Americans have lower survival rates than Caucasians. Due to the early discovery of lip cancer, the standard treatment modality is surgical resection, which explains the significantly decreased survival related to adjuvant chemo(radio)therapy. So we recommend to avoid the systemic therapy for less unfavrouble side effect.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract